『Weekly, Mon 9 Nov: A survival win, a billion-dollar deal, an Ebola push. What's real?』のカバーアート

Weekly, Mon 9 Nov: A survival win, a billion-dollar deal, an Ebola push. What's real?

Weekly, Mon 9 Nov: A survival win, a billion-dollar deal, an Ebola push. What's real?

無料で聴く

ポッドキャストの詳細を見る
概要

Akeso’s ivonescimab, Genrix’s early lupus data and Ebola vaccine candidates: evidence, money and delivery across this week’s East–West biotech news. China review is not approval; early uncontrolled lupus responses are not comparative benefit.

Full transcript and all sources for this episode

Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil reports no holdings in companies mentioned.

Research cut: 9 Nov 2026, 05:55:43 SGT. Weekly retrospective: 2–8 Nov.

0:00 Introduction and AI-voice disclosure
1:15 Akeso: evidence versus review
5:16 Hemay and deal payment structures
9:32 iX: licences and the next document
10:45 Ebola: trial evidence and delivery
13:41 BionicM, Mindtrix and egg proteins
19:40 Genrix: early lupus evidence
21:13 The next evidence to watch

Key sources: Akeso: China priority review, 5 Nov; WHO: Tumaini candidates, 4 Nov; China lupus trial registry; Cullinan: interim China lupus data, 8 Nov. Sponsor-reported interim lupus data and all original sources are linked in the transcript.

Weekly roundup: subscribe to The East–West Bio Brief on LinkedIn.

Also listen on Apple Podcasts, Amazon Music and YouTube.

Which uncertainty did an announcement actually remove—and what evidence should come next?

adbl_web_anon_alc_button_suppression_t1
まだレビューはありません